Pharmaceutical market launch structuring for a French OTC manufacturer entering a CIS market. Advisory on distribution model, regulatory circulation control and operational launch execution.
Context
Pharmaceutical market launch structuring becomes critical when the regulatory and commercial steps have been completed but the product still cannot reach the end consumer in a controlled and repeatable way. This case involved exactly that gap.
A mid-sized French pharmaceutical manufacturer with annual revenue of approximately EUR 120 million and a portfolio of over 40 OTC products and medical devices across European and selected international markets had completed product registration, pricing approval and technical launch preparation for three product lines in a CIS market. The registration process alone had taken over 14 months and required significant investment in documentation, local testing and regulatory liaison. The company's international division, a team of 12 people managing 15 export territories from the Paris headquarters, had coordinated the entire pre-launch phase and secured commercial interest from two national pharmaceutical wholesalers and several regional distributors.
Despite all of this, sales did not start. The wholesalers were willing to purchase and resell, but pharmacies, the final point of consumer access, required a clearly defined post-import responsibility model before they would stock the products. In this market, pharmacies bore direct regulatory accountability for any product complaint, recall or adverse event reported by a consumer. Without a documented chain of responsibility connecting the manufacturer, the importer and the point of sale, pharmacy chains simply refused to list the products regardless of commercial attractiveness.
The distributors, for their part, were structured as commercial intermediaries. They handled logistics, invoicing and resale. They did not have the regulatory infrastructure, the quality management systems or the organisational willingness to assume pharmacovigilance obligations, batch recall coordination or reverse logistics for returned or expired products. They had made this clear during contract negotiations, and the manufacturer's legal team in Paris confirmed that forcing these obligations onto a standard wholesale partner would be both legally fragile and commercially destructive to the relationship.
Headquarters had allocated a nine-month launch window. The international division director had presented the CIS territory to the executive committee as a growth market with confirmed registration, established distributor relationships and a clear path to first revenue. If stable reorder cycles did not materialise within that window, internal policy required the territory to be reclassified as structurally non-viable and removed from the active operating portfolio. The registration investment, approximately EUR 180,000 across three product lines, would be written off, and re-entry at a later stage would require starting the regulatory process from the beginning.
The question was therefore not whether the market was attractive. It was whether the product could physically circulate in a controlled, compliant and repeatable manner, and whether the operating model for that circulation could be built within the time and budget constraints the company was operating under.
Why the Company Could Not Solve This Internally
The international division had deep experience in market entry through distributor-led models in Western European and North African markets. In those territories, the regulatory infrastructure was either harmonised with EU standards or the distributor assumed a broader operational role as a matter of market practice. The CIS market operated under a different logic. Post-import regulatory responsibility did not automatically transfer to the distributor upon purchase. It remained with the entity that controlled the product's market presence, and in the absence of a clearly designated responsible party, it defaulted to whichever organisation the regulator could identify as the last documented point of control.
The company's regulatory affairs department understood the pharmacovigilance and recall obligations in theory but had no operational framework for managing them in a market where they had no local legal entity, no local staff and no direct relationship with the pharmacy chains that would ultimately stock the product. The legal team could draft contractual language, but the core problem was not contractual. It was operational: who would physically manage release supervision, batch tracking, complaint handling, recall logistics and product returns in a market 3,000 kilometres from headquarters, and how would that function be structured so that distributors could operate commercially without bearing regulatory exposure they were unwilling to accept.
Tretiakov Consulting was engaged because the situation required someone who understood both the commercial expectations of a European pharmaceutical headquarters and the operational and regulatory realities of launching consumer health products in a CIS distribution environment. The practice brought direct experience in structuring market entry and distribution operating models in markets where standard European assumptions about distributor roles, regulatory responsibility and supply chain control do not apply. Critically, the engagement required not just advisory on the model design but hands-on operational involvement in building the circulation infrastructure and supporting the first commercial cycles on the ground.
How the Work Was Structured
The engagement began with a detailed mapping of where control over the product disappeared after the first sale. Every step from manufacturer shipment to pharmacy shelf was documented, and at each transition point the engagement assessed who held physical custody, who held regulatory accountability, who held documentation authority and whether there was alignment between these three dimensions.
The analysis confirmed that in the standard distributor model the company was attempting to use, accountability fragmented at the point of wholesale resale. The wholesaler received the product, stored it under its own warehouse licence, sold it to pharmacies under its own commercial terms, and from that point forward neither the manufacturer nor the wholesaler had operational visibility into where each batch was located, whether storage conditions were maintained, or how a recall would be executed if required. The pharmacies, aware of this gap, were protecting themselves by simply not listing the products.
Three operating models were evaluated:
Shipping through the existing wholesaler network with enhanced contractual language was rejected. Adding pharmacovigilance clauses to a standard distribution agreement did not create the operational capability to execute those obligations. The wholesalers lacked the systems, staff and motivation to manage regulatory functions they had never performed.
Establishing a local subsidiary was rejected. It would have required company registration, local hiring, office setup, regulatory licence application and warehouse qualification, a process that would take 8 to 12 months and impose fixed monthly costs of approximately EUR 15,000 to 20,000 before a single unit was sold. Given that demand stability had not yet been proven, headquarters was unwilling to approve this level of commitment.
The model that was adopted centred on a dedicated circulation operator. This was a locally licensed entity, independent from the distributor chain, that assumed responsibility for release supervision, batch tracking, pharmacovigilance case processing, complaint management and reverse logistics. The circulation operator did not buy or resell the product. It managed the product's regulatory presence in the market while the distributors continued to handle commercial activities, warehousing and resale under their existing licences.
The contractual architecture connected three layers. The manufacturer maintained a direct agreement with the circulation operator covering all regulatory and quality obligations. The circulation operator maintained service agreements with each distributor defining documentation flows, batch reporting requirements and recall procedures. The distributors maintained their standard commercial relationships with pharmacies but could now demonstrate to pharmacy procurement teams that a documented, locally accountable regulatory chain existed behind the products they were offering.
Tretiakov Consulting designed the full operating model, identified and evaluated the circulation operator candidate, structured the three-layer contractual framework, and coordinated the alignment between the manufacturer's Paris-based regulatory affairs team, the local circulation operator and the two primary wholesale partners. The practice then remained operationally involved through the first three shipment cycles to ensure that documentation flows, batch release procedures and pharmacy listing processes functioned as designed under real commercial conditions.
What the Engagement Produced
The first commercial shipment was dispatched within five months of the engagement start, compared to the nine-month internal deadline. The reduction in timeline was driven by the practice's ability to design and implement the circulation model in parallel rather than sequentially, the existing network of local regulatory and operational contacts that accelerated operator identification and qualification, and direct involvement in distributor and pharmacy chain negotiations that would otherwise have required multiple rounds of correspondence between Paris and the local market.
Within three months of first shipment, both primary wholesalers had moved from trial orders to planned monthly replenishment. Four pharmacy chains representing approximately 340 retail locations had listed the products, and the first reorder cycle completed without incident. The manufacturer's pharmacovigilance team in Paris received structured monthly reports from the circulation operator rather than ad hoc communications from distributors who had previously been unable or unwilling to provide regulatory data.
Headquarters reclassified the territory from experimental launch status to managed operating presence. The exception-based shipment approval process, under which each individual order required executive committee sign-off, was replaced by routine supply planning managed by the international division. The CIS market was included in the company's 18-month commercial development plan for the first time.
The total cost of the circulation model, including operator fees, regulatory setup and the advisory engagement, was approximately EUR 65,000 for the first year, less than half the estimated annual cost of a local subsidiary and with no fixed headcount commitment.
Why This Case Matters
This engagement illustrates a pattern common in pharmaceutical and regulated consumer product market entry: the company completes every preparatory step correctly, registration, pricing, partner identification, commercial agreements, and then discovers that the last mile, getting the product to circulate in a controlled and compliant manner, requires an operating architecture that no one on the internal team has built before.
What made the advisory valuable was not regulatory expertise in isolation but the ability to connect the commercial expectations of a European headquarters operating under corporate governance pressure with the operational and regulatory mechanics of a CIS market where distribution infrastructure, regulatory accountability and pharmacy procurement practices follow a fundamentally different logic. The practice's direct operational involvement during the launch phase, not as an observer but as a working participant in the first shipment cycles, was the element that converted a theoretical operating model into a functioning commercial presence.
